Prediction of IVF cycle success with antimullerian hormone levels by Merlotti, Lindsay
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
Prediction of IVF cycle success with
antimullerian hormone levels
https://hdl.handle.net/2144/31257
Boston University
	 	 	
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
PREDICTION OF IVF CYCLE SUCCESS WITH ANTIMULLERIAN 
HORMONE LEVELS 
 
 
by 
 
 
 
 
LINDSAY MERLOTTI 
 
B.S.E., University of Michigan, 2015 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2018  
	 	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2018 by 
 Lindsay Merlotti 
 All rights reserved  
	 	 	
Approved by 
 
 
 
 
First Reader   
 Wendy Kuohung, M.D. 
 Associate Professor of Obstetrics and Gynecology 
  
 
 
Second Reader   
 John Rinehart, M.D., Ph.D., J.D. 
 Senior Clinician Educator of Obstetrics and Gynecology 
 Pritzker School of Medicine, University of Chicago 
 
 
 
		 iv 
PREDICTION OF IVF CYCLE SUCCESS WITH ANTIMULLERIAN 
HORMONE LEVELS 
LINDSAY MERLOTTI 
ABSTRACT 
Background: Current estimates indicate approximately 6.7% of women in the US 
are infertile.  Infertility can arise from many different conditions and can be both 
attributed to male and female factors.  In women, measures of ovarian reserve 
such as AMH level or FSH level on day three of the menstrual cycle can be used 
to predict reproductive success.  In conjunction with additional tests and lifestyle 
screening, these values help to guide the course of treatment, with some patients 
moving eventually to in vitro fertilization.  In vitro fertilization therapy is cost-
prohibitive if the patient does not have insurance coverage, an issue for the 
majority of patients across the United States. 
Aims: To evaluate the correlation between cycle number, age, and AMH level 
with achieving a successful live birth through a statistical analysis of over 50,000 
cycles of in vitro fertilization.  
Methods: Data was obtained from Practice Highway, a company that owns the 
electronic medical record (EMR) program eIVF, used by over 140 reproductive 
endocrinology practices across the country.  The database provided a total of 88 
		 v 
variables and 138,526 IVF cycle observations ranging from 01/01/2005 to 
09/09/2015.  A thorough review of available literature was performed to 
determine the need for the correlations analyzed in this paper. Utilizing this 
information in conjunction with the scope of this paper, the number of variables 
was reduced to four.  Linear regression and multivariate regression was 
performed on the four main study variables to identify possible correlations. 
Results: The results of our study indicate that there is not a strong correlational 
relationship between the variables analyzed.  There was not a significant 
correlation between age and whether a live birth was achieved. As expected, the 
strongest relationship identified through our study is the decrease in AMH as 
age increases. 
Conclusions: Our study results indicate that there is no correlation between 
AMH and live birth, suggesting that this biomarker alone is insufficient to be 
used by physicians as a means of advising patients on IVF success.  Additionally, 
measures such as number of cycles completed and age at cycle start can be useful 
when counseling patients on their probability of success with assisted 
reproductive technologies. 
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INTRODUCTION 
 
Prevalence and Causes of Infertility Today 
Currently, the Center for Disease Control (CDC) estimates that 6.7% of 
women between the age of 15 and 44 years old are infertile (“NSFG - Listing I - 
Key Statistics from the National Survey of Family Growth,” n.d.).  Infertility is 
defined as unprotected intercourse for 12 consecutive months without achieving 
a pregnancy that results in a live birth in a woman who has not undergone a 
procedure for surgical sterilization (“NSFG - Listing I - Key Statistics from the 
National Survey of Family Growth,” n.d.).  This is also known as primary 
infertility.  Secondary infertility refers to the inability to become pregnant or 
carry a pregnancy to a live birth after a previous pregnancy resulted in a live 
birth (“WHO | Infertility definitions and terminology,” n.d.). Problems 
conceiving can arise due to issues in both male and female partners. A 
breakdown of the most common causes is illustrated in Figure 1.    
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Figure 1: A Breakdown of the Common Causes of Infertility. Female infertility 
accounts for approximately 50% of the causes of infertility (Knuttinen, Jajko, & 
Scoccia, 2014).  
 
Causes of male factor infertility include abnormal sperm production and 
function such as abnormalities in sperm morphology, inability to deliver sperm 
as with erectile dysfunction, certain diseases such as cancer, or overexposure to 
environmental toxins such as certain medications or pesticides and other 
chemicals.  Causes of female infertility include ovulation disorders caused by 
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conditions such as polycystic ovarian syndrome or hyperprolactinemia, 
structural abnormalities in the uterus or cervix such as polyps and fibroids, 
damage or blockage of the fallopian tubes, endometriosis, primary ovarian 
insufficiency that results in early menopause, pelvic adhesions, or other 
conditions such as cancer that mandate extirpation of reproductive 
organs(“Infertility - Symptoms and causes - Mayo Clinic,” n.d.). 
 
Background on Assisted Reproductive Technologies 
Since their development in 1978, in vitro fertilization (IVF) and embryo 
transfers (ET) have resulted in the birth of over 4 million babies (Biggers, 2012).  
The first cycles of assisted reproductive technologies (ART) were completed 
using the natural hormonal cycle of a woman to retrieve one egg (Pacchiarotti et 
al., 2016).  Current practice uses medications such as recombinant follicle 
stimulating hormone (rFSH) and recombinant human menopausal gonadotropin 
(rHMG), that contains a one to one ratio of luteinizing hormone (LH) to FSH 
activity, to stimulate the ovaries in a controlled fashion as a way to increase the 
number of oocytes retrieved in a given cycle (Alper & Fauser, 2017).   
In a natural menstrual cycle, the hormones FSH and LH act on the 
granulosa cells and theca cells respectively of ovarian follicles to facilitate 
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folliculogenesis and dominant follicle selection (Baerwald, Adams, & Pierson, 
2012).  Gonadotropin releasing hormone (GnRH) secretion in a pulsatile fashion 
from the hypothalamus causes the release of FSH and LH by stimulating the 
anterior pituitary as summarized below in Figure 2.  
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Figure 2: Hypothalmic-Pituitary-Gonadal Axis. The release of GnRH from the 
hypothalamus acts on the anterior pituitary to increase production of FSH and LH. These 
hormones in turn act to increase steroid production in the ovaries. Depending on the time 
of the cycle, estrogen may be inhibitory (early follicular phase and late luteal phase) or 
stimulatory (late follicular phase and ovulation) (Barbieri, 2014). 
 
Medications such as GnRH agonists and antagonists are used to prevent 
premature ovulation by inhibiting a natural LH surge (Wang, Lin, Wang, Qian, & 
Zhou, 2017).  Wang et al. (2017) also determined that the use of GnRH 
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antagonists in ART protocols has decreased the incidence of ovarian 
hyperstimulation syndrome (OHSS) by permitting the use of GnRH agonist 
instead of hCG (human chorionic gonadotropin) to trigger oocyte maturation.  In 
an IVF cycle, when ovarian follicles have reached an optimal size, final oocyte 
maturation and ovulation can be induced using hCG, GnRH agonist, or a 
combination of both.  HCG has similar actions as LH at the level of the LH 
receptor but has a longer half life; as such hCG is the preferred medication for 
triggering oocyte maturation except in cases at high risk for OHSS (Alper & 
Fauser, 2017). 
 
Predictors of IVF Outcomes and Success 
Biomarkers 
Physicians use various biomarkers, patient age, and lifestyle factors to 
counsel patients on their probability of success when moving to IVF.  One such 
biomarker is anti-mullerian hormone (AMH), an indicator of ovarian reserve.  
AMH is a homodimeric glycoprotein hormone that is part of the transforming 
growth factor beta superfamily.  Granulosa cells of pre-antral and small antral 
follicles in the ovaries secrete AMH, which plays a role in follicular maturation is 
depicted in Figure 3 (Garg, Deepika & Tal, Reshef, 2016).  Mice lacking AMH 
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have demonstrated a faster primordial follicular recruitment rate and earlier 
depletion of ovarian reserve, suggesting AMH has an inhibitory effect on 
maturation (Dewailly et al., 2014). 
 
 
 
Figure 3:  The production of AMH and its actions during the development of a 
dominant follicle. Pre-antral follicles and small antral follicles release AMH, which 
inhibits FSH action, reducing the rate of follicular maturation and recruitment. 
Expression of AMH decreases once the follicles reach the large antral follicle stage. This 
allows FSH to act upon the follicle to increase production of estradiol (E2), which 
eventually leads to dominant follicle selection and ovulation (Garg, Deepika & Tal, 
Reshef, 2016). 
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As a woman’s age increases, AMH secretion decreases, making it a 
clinically useful measurement of ovarian reserve and in predicting the timing of 
menopause (Dewailly et al., 2014).  This measurement is also useful when 
selecting a protocol for controlled ovarian stimulation in IVF (Dewailly et al., 
2014).  A low AMH level may be an indication that a patient will have poor 
ovarian response to gonadotropins, while a high AMH level suggests an 
increased risk of OHSS.  
Alongside AMH, antral follicle count (AFC), early follicular FSH and 
estradiol (E2), and inhibin B are also utilized as indicators of ovarian reserve.  An 
AFC is the ultrasound evaluation of preantral follicles in the ovaries and is 
considered one of the most reliable markers used to indirectly measure the 
ovarian reserve (Chai et al., 2015).  FSH levels rise as women approach 
menopause, and therefore an elevated FSH level is indicative of decreased 
reproductive potential.  Clinicians measure FSH levels, in conjunction E2 levels, 
on day three of the menstrual cycle to assess ovarian reserve.  Studies have 
established a link between poor IVF outcome and abnormal day three lab results 
(Kaser, Goldman, Fung, Alper, & Reindollar, 2014).  Finally, inhibin B, like AMH, 
is released by granulosa cells and provides feedback inhibition of FSH in the 
early follicular phase (Steiner et al., 2017).  Lower levels of inhibin B lead to an 
	9 
early rise in FSH during the follicular phase, shortening the follicular phase and 
the menstrual cycle as a whole. A shorter menstrual cycle has been associated 
with a reduced probability of conception both naturally and via ART cycles 
(Steiner, 2013).  
 
Age-Impacted Factors 
 Age is a major factor considered by reproductive clinicians when 
counseling patients on recommended courses of treatment.  It has been estimated 
that 19% of women who are undergoing ART cycles in the United States are 
above the age of 40 years (Kim, Sung, & Song, 2017).  As with ovarian reserve, 
oocyte quality declines with age.  The relationship between the age-related 
decline in oocyte quality and oxidative stress has been established through 
research (Mihalas, Redgrove, McLaughlin, & Nixon, 2017).  Furthermore, the risk 
of aneuploidy, birth defects, and miscarriage increases as a woman ages.  For 
example, the incidence of trisomy, having three copies of a chromosome instead 
of two, has a low incidence of 2-3% in women in their 20s.  As a woman 
approaches 40, the incidence of trisomy increases to 35% (Chiang, Schultz, & 
Lampson, 2012).  While preimplantation genetic testing (PGT) is available to 
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screen embryos for diseases and aneuploidy, it is an expensive addition to an 
already expensive process that many patients cannot afford. 
Although slower to decline in quality than oocytes due to continual 
production, sperm in men over the age of 50 years old have increased DNA 
damage, leading to lower rates of blastocyst development and increased rates of 
aneuploidy in embryos created using donor oocytes when compared to those 
created using samples from younger men (Javier García-Ferreyra et al., 2015).   
In addition, the number of embryos transferred impacts the probability of 
achieving a pregnancy.  Currently, the American Society of Reproductive 
Medicine (ASRM) recommends that one embryo be transferred for women under 
the age of 35, with a limit of two embryos per transfer (Dialog, 2017).  These 
recommendations change in women above the age of 35, as summarized in the 
table below:  
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Table 1: Recommended limits on the number of embryos to transfer. Favorable 
is defined as embryos from the first cycle of IVF, good quality embryos, additional 
embryos are available to be cryopreserved, or embryos from a previously successful cycle 
(Dialog, 2017). 
 
Prognosis <35 yrs old 35-37 yrs 38-40 yrs 41-42 yrs 
Cleavage-stage 
embryos 
    
   Euploid 1 embryo 1  embryo 1 embryo 1 embryo 
Other Favorable 1 embryo 1 embryo ≤	3 embryos ≤ 4 embryos 
   All others ≤ 2 embryos ≤ 3 embryos ≤ 4 embryos ≤ 5 embryos 
Blastocysts     
   Euploid 1 embryo 1  embryo 1 embryo 1 embryo 
Other Favorable 1 embryo 1  embryo ≤ 2 embryos ≤ 3 embryos 
   All others ≤ 2 embryos ≤ 2 embryos ≤ 3 embryos ≤ 3 embryos 
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 These guidelines aim to limit multiple gestations and their concomitant 
higher risk of gestational diabetes, preeclampsia, premature birth, and low birth 
weight (Pandian, Marjoribanks, Ozturk, Serour, & Bhattacharya, 2013).   
 Additionally, the number of cycles completed may impact the probability 
of achieving success.  While not directly related to age, women who are older 
may undergo more IVF cycles in the attempt to create more euploid embryos.   
Studies have shown that the cumulative live birth rate (CLBR) increases with 
successive IVF cycles completed, as can be seen in the Figure 4.  In this 
population- based study, the CLBRs were distinguished as conservative and 
optimal. Conservative CLBR estimates were calculated under the assumption 
that women who discontinued treatment had no potential for a live birth. 
Alternately, the optimal CLBR estimates were calculated under the assumption 
that these women still had the potential for a live birth equal to those who 
continued with treatment (McLernon, Maheshwari, Lee, & Bhattacharya, 2016).  
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Figure 4:  Cumulative Live Birth Rates (CLBRs) from 1992-2007. Graph A 
demonstrates the conservative estimates of CLBR while Graph B is the optimal 
estimates of CLBR from a population-based study of IVF cycle data from 178,898 
women (McLernon et al., 2016).  
 
Lifestyle and Other Factors 
Lifestyle factors such as smoking, nutrition habits, and body mass index 
(BMI), as well as type of infertility (primary vs. secondary) have also been shown 
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to impact success in a given ART cycle.  Studies show non-smokers are 
significantly more likely to achieve pregnancy and live births than smokers, and 
women with BMIs under 25 are more likely to achieve pregnancy and live birth 
than women whose BMI is greater than or equal to 25 (Purewal, Chapman, & 
Van Den Akker, 2017).  There is no direct link between alcohol use and IVF 
outcome success. However, it has been shown that with poor nutrition habits,     
cigarette smoking, and alcohol use, reactive oxygen species (ROS) production 
increases overall and leads to increased oxidative stress, which may lower IVF 
success (Firns et al., 2015).   
Furthermore, psychological disposition, stress, anxiety, and exercise may 
impact IVF cycle success.  As discussed by Rossi et al. (2016), there is a 
correlation between greater positive affect and cycle success, with a 7% decrease 
in the risk of cycle failure. Conversely, stress and general anxiety were 
demonstrated not to always negatively impact IVF cycle success (de Klerk et al., 
2008).  The effect of a sedentary lifestyle vs. physical activity on the probability of 
a live birth following IVF has been evaluated.  Some forms of physical exercise 
such as aerobics have been linked to an increase in cycle success, but there was 
no correlation between a sedentary lifestyle and decreased IVF success (Gaskins 
et al., 2016). 
	15 
Costs of ART Cycles 
 It has been estimated that 12% of American women will undergo some 
form of infertility treatment in their lifetime, with 1-2% pursuing IVF (Katz et al., 
2011).  In 2009, the cost of IVF treatment per live birth in the US was $41,132, 
among the highest in the world (Chambers, Sullivan, Ishihara, Chapman, & 
Adamson, 2009).  Unfortunately, most insurance companies nationwide do not 
cover many of these costs.  The state of Illinois became one of the few mandated 
coverage states in 1991, meaning employers are required to provide infertility 
benefits in their health insurance policies for employees (“In Vitro Fertilization 
Coverage,” n.d.). Furthermore, treatment for infertility was also determined to be 
an essential benefit under the federal Affordable Care Act (“Insurance Coverage 
for Infertility Treatment,” n.d.).  However, there are many exemptions to 
infertility treatment coverage that allow employers to circumvent this mandate, 
including companies smaller than 25 employees, religious institutions or 
institutions with religious affiliations, or companies that are self-insured.   
Current expenditures in IVF cover laboratory tests and equipment, 
medications, procedures, and treating complications from IVF (Teoh & 
Maheshwari, 2014).  During a cycle, multiple monitoring ultrasounds and 
laboratory blood tests must be completed to monitor the progress of stimulation. 
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Monitoring tests contribute to the costs in addition to medications. Without 
insurance coverage, injectable medications used in in vitro fertilization can cost 
more than $5,000 per cycle, with medications costing an average of $3,154 in 2006 
(Chambers et al., 2009).    
 Klitzman (2017) interviewed patients undergoing ART procedures and 
found that 49% were planning on using retirement funds, 32% went into debt, 
and cost had an influence on treatment choices for at least 37%. The cost 
constraints and emotional effects of IVF need to be taken into consideration 
when counseling couples considering IVF. With the current state of insurance 
coverage in the United States, physicians need guidelines for advising patients of 
every age on whether IVF treatment will benefit them and how many cycles they 
should pursue before moving on to alternative options of starting a family. 
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SPECIFIC AIMS 
 
As current literature is inconclusive in determining the relationship 
between AMH and pregnancy outcome, making it hard for physicians to use this 
test in their clinical decisions, we aimed to evaluate the correlation between cycle 
number, age, and AMH level with achieving a successful live birth through a 
statistical analysis of over 50,000 cycles of in vitro fertilization. 
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METHODS 
 
Data Acquisition 
 Data used in this retrospective study was obtained from Practice 
Highway, a company that owns the electronic medical record (EMR) program 
eIVF.  This EMR is used by over 140 IVF practices across the country.  Practice 
Highway was able to create a database of IVF cycles from various practices to be 
used by investigators. The database provided had a total of 88 variables and 
138,526 IVF cycle observations ranging from 01/01/2005 to 09/09/2015.  As data 
was completely deidentified, institutional review board approval for human 
subjects research was not required.  A complete list of all the variables available 
in the eIVF database can be found in the table below:  
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Table 2: Complete List of Variables Available in Original Database. 
Actual_FHB Endo_Type Pos 
Actual_Sacs EP Pregnancy_Info_Source 
AFC_Left Freeze_All Pregnancy_Outcome 
AFC_Right Gravida Pregnancy_Test 
Age_At_Cycle_Start Height Protocol 
AMH Height_inch Protocol_Type 
Avg_Foll_Size Insem_Method Ptn_Current_Age 
Biochemical Last_bHcg_Value Reduction 
BMI LiveBirth Reduction_Date 
Clinical Low_Oxygen Retrieval_Date 
Customer Max_E2 SAB 
Customer_ID Max_Foll_Size Sperm_Concentration 
Cycle_Drgus Min_Foll_Size Sperm_Motility 
Cycle_Number No_2_PN Sperm_Source 
Cycle_Order_ID No_GV Sperm_Volume 
Cycle_Outcome No_MI TAB 
Cycle_Status No_MII Total_Cryoed 
D5_Blast Nos_Born Total_Folls 
Day3_FSH Nos_FHB Total_Folls_GT14 
Delivered Nos_FHB_Post_Redu
ction 
Total_Folls_GT15 
Dnr_Embryo_Age_At_Cycle_S
tart 
Nos_Gestation Total_Folls_LT15 
Dx_1 Nos_ICSI Total_FSH 
Dx_2 Nos_Inseminated Total_Gonadotropin 
Dx_3 Nos_IVF Total_hMG 
E2_at_HCG Nos_Reduction Transfer_Count 
E2_next_HCG Ongoing Treatment_Outcome 
eIVF_Patient_ID Oocytes_Cryoed Weight 
Embryo_Source Oocytes_Retrieved Weight_Lbs 
Embryos_Cryoed Parity_Full_Term  
Endo_Thickness Parity_Pre_Term  
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Selection of Study Variables and Valid Data 
 Our literature review and the aim of this thesis led us to select four 
variables from 88:  AMH, age at cycle start, cycle number, and live birth 
(“delivered”). Further inspection of the data eliminated outliers such as a value 
of 0 years for age at cycle start, an impossible value for proceeding with an IVF 
cycle.  
 
Statistical Analyses 
 Statistical analysis of the data was completed using the statistics software 
package R.  Data analysis was first performed to summarize the data graphically. 
Additionally, linear regression was performed on each of our independent 
variables (AMH, age at cycle start, and cycle number) versus our dependent 
variable of live birth.  This analysis also allowed for the determination of the 
correlation coefficients for the relationship between each variable analyzed. 
Finally, multivariate linear regression was also performed using this software to 
evaluate the relationship between potential confounders like AMH, age at cycle 
start, and cycle number on delivery potential.   
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RESULTS 	
Evaluation for completeness of values for the variables selected, in 
conjunction with elimination of outliers, reduced the total number of 
observations analyzed from 138,526 cycles to 51,403 cycles.  49 cycles were 
omitted as they were entered under the date 01/01/1900, which was viewed as an 
error in data entry.  
 
Minimum and Maximum Values Seen in Data 
 The following table summarizes the minimum, maximum, and average 
values of the data studied for each variable evaluated in our study: 
 
Table 3: Summary of Data Values for Variables Studied.  
Variable Minimum Maximum Average 
Age at start of the 
cycle 
14 years old 56 years old 35.6 years old 
Cycle number 1st cycle (no 
previous cycles 
completed) 
26th cycle 2nd cycle 
AMH level 0 ng/dL 
(undetectable) 
258 ng/dL 2.79 ng/dL 
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The variable delivered was evaluated in a binary fashion, with 0 
indicating there was not a successful delivery and 1 indicating there was a 
successful delivery resulting in a live birth. 
 
Completeness of Data Studied 
 A systematic review of the data used in this study indicates that there 
were no missing values   for the following variables: the age of a woman at the 
start of her IVF cycle, the number of the IVF cycle analyzed, her serum AMH 
level, and whether or not she delivered a child. 
 
Occurrence of Values in Data 
The frequency of a value appearing was also evaluated for each variable. 
As demonstrated in Figure 6, most women began cycles between the ages of 30 
and 40 years old. Furthermore, the number of cycles completed by each woman 
fell around 2 cycles. AMH values above 10 ng/dL were rare, with most levels 
between 0 ng/dL and 5 ng/dL. Finally, the frequency of women delivering a 
successful pregnancy was much less than those not delivering 
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Figure 5: Graphical representation of data for total number of cycles evaluated, 
AMH level, cycle number, age at cycle start, and delivered. Controlling for 
statistical outliers, the relative frequency of each value can be seen for the 
variables analyzed.  
 
 
Correlation Relationships Between Variables 
An analysis of the correlations between each variable revealed the 
correlation coefficients as seen below in Table 4. As suggested by the correlation 
coefficient, there is not a significant relationship between the value of AMH and 
whether or not a woman will achieve a delivery. Furthermore, the correlation 
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coefficient of -0.32 suggests that there is a weak negative relationship between 
AMH value and the age at cycle start.  There is a positive relationship between 
cycle number and age at cycle start, while there appears to be a weak negative 
relationship between cycle number and chance of delivery. The coefficient values 
displayed in Table 4 below suggest that the strongest correlation in our study is 
between age at cycle start and AMH. 
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Table 4: Correlation coefficients between each variable evaluated in the study. 
A value of 1 indicates a strong, positive correlation between the variables 
evaluated. A value of -1 indicates a strong, negative relationship between the 
variables analyzed. As the correlation coefficient approaches 0, the strength of 
the relationship between two variables decreases. 
 
 
 
Single-Variable Linear Regressions   
Age at Start of Cycle vs. Delivered 
 When a linear regression was performed between the age at the start of  
the cycle and whether there was a live birth, the correlation coefficient -0.138 indi
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cated there is not a strong relationship between these values.    The adjusted R-sq
uared value of 0.017 with a p-value of <2.2e-16 indicates that there was not a stati
stically significant relationship between age at cycle start and live birth. 
 
Cycle Number vs. Delivered  
 The linear regression of our data comparing cycle number vs. delivered 
led to an adjusted R-squared value of 0.001446 with a p-value of <2.2e-16.  
Further evaluation combining age at the start of the cycle and cycle number vs. 
delivered resulted in an adjusted R-squared value of 0.01722.  Both regressions 
revealed that there is not a statistically significant relationship between cycle 
number and delivered or between age plus cycle number and delivered. 
 
AMH Level vs. Delivered  
 The adjusted R-squared value for AMH vs. delivered with a p-value of 
<2.2e-16 was 0.002119. The adjusted R-squared value improved to 0.01701 with 
the addition of age as a variable in this regression. However, both results 
revealed that there is not a statistically significant relationship between these 
variables. 
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Multivariate Regression of Age at Start of Cycle, Cycle Number, and AMH vs. 
Delivered 
 
 When a multivariate linear regression was performed comparing age at 
start of cycle, cycle number, and AMH level vs. delivery, results showed an 
adjusted R-squared value of 0.001419 with a p-value of <8.577e-16. This analysis 
indicated there is not a strong correlation between these variables. 
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DISCUSSION 
In women undergoing fertility treatment and in vitro fertilization, 
measures of ovarian reserve such as AMH level or FSH level on day three of the 
menstrual cycle are used to predict reproductive success.  To evaluate the 
correlation between cycle number, age, and AMH level with achieving a 
successful live birth, we performed a retrospective analysis of over 50,000 cycles 
of in vitro fertilization nationwide from a large database.  To identify possible 
correlations, linear regression and multivariate regression was performed on the 
four main study variables of age, cycle number, AMH level, and achievement of 
live birth.  We found that there was not a strong correlational relationship 
between the variables analyzed; the strongest relationship identified through our 
study is the decrease in AMH as age increases. 
 
   
Correlation between AMH and Live Birth 
As discussed by Santoro (2017), studies evaluating the impact of AMH on 
clinical pregnancy monitor the time to reach a positive pregnancy test and do not 
follow the pregnancy through to the final outcome of live birth.  Current studies 
have been contradictory in determining whether there is a correlation between 
clinical pregnancy and AMH as well as a correlation between AMH and live 
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birth rate (Szafarowska, Molinska-Glura, & Jerzak, 2014). Goswami & Nikolaou 
(2017) determined that there is not a correlation between AMH level and live 
birth rate in women under the age of 35.  However, above this age, AMH was 
relevant.  Similarly, Szafarowska, Molinska-Glura, & Jerzak (2014) found that 
AMH concentration may not be a reflection of oocyte quality and live birth rate.  
Furthermore, they postulated that a high AMH might negatively impact 
pregnancy rates.  Like Goswami & Nikolau, our study found no correlation 
between AMH and live birth. 
 
Counseling Patients Using Age and Cycle Number 
 A number of studies have evaluated the cumulative live birth rate based 
on age and total number of subsequent IVF cycles completed.  Chambers et al. 
(2017) found that the cumulative live birth rate decreases with increasing age and 
number of cycles completed, studying rates of live birth in up to 8 subsequent 
cycles.  Additionally, they determined that cycle-specific rates of birth decreased 
with each subsequent cycle.  As discussed by Smith, Tilling, Nelson, & Lawlor 
(2015), currently most practices limit the number of IVF cycles to around three 
transfers.  Their study found that in women under the age of 40, the cumulative 
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live birth rate is up to 68.4% over six cycles.  However, by the age of 42, the live 
birth rate decreases significantly to only 4% (Smith et al., 2015).   
    
Limitations of our study 
 Our study had a number of limitations.  First, we did not control for cycle 
number or limit all cycles analyzed to a specific cycle number.  This may have 
impacted our outcomes as a woman’s initial IVF cycle has an inherently lower 
success rate as protocol selection is empiric by necessity in a patient who has 
never undergone this type of treatment.  The provider may determine that a 
protocol adjustment is required for success of a subsequent cycle.  In our study, 
type of AMH laboratory test was not controlled for, allowing there to be in-
group variation on the measured levels and their representation of ovarian 
reserve.  Additionally, as this was a retrospective study, we did not control the 
time in the menstrual cycle that AMH was measured and whether there was 
exposure to agents such as combined oral contraceptives that may impact the 
result. As discussed by Leader & Baker (2014), AMH does fluctuate throughout 
the menstrual cycle, and results have significant variability depending on type of 
laboratory test performed and recent contraceptive use.  Unlike other studies, we 
did not take into account the type of infertility diagnosis, that may impact live 
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birth outcome significantly.  Furthermore, as discussed in the introduction, 
lifestyle factors such as BMI and history of smoking were not used in our 
evaluations.   
 
Conclusion and Implications for Future Research 
 Our study results indicate that there is no correlation between AMH and 
live birth, suggesting that this biomarker alone is insufficient to be used by 
physicians as a means of advising patients on IVF success.  In the future, studies 
may control for laboratory method of AMH measurement or evaluate the change 
in AMH over time.  Using the rate of change of AMH level in an individual may 
be a better use of AMH as a predictor of live birth outcome.  Studies may be done 
to evaluate how an AMH level correlates to oocyte quality, an integral 
component of achieving a successful pregnancy both naturally and through an 
ART procedure. Recent studies such as La Marca et al. (2017) have determined 
that there is a positive age-independent correlation between serum AMH level 
and the number of euploid embryos retrieved during a given IVF cycle. 
Additionally, studies such as Tal, Seifer, Wantman, Baker, & Tal (2018)  have 
looked at AMH as a predictor of overall live birth outcomes per embryo transfer. 
However, given the increasing use of PGT, there is an opportunity for 
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investigation into reproductive potential per retrieval using AMH level and 
euploid embryo rate. In the future, it may be beneficial for studies to further 
investigate how a given AMH level correlates with the number of euploid 
embryos and live births per retrieval and how then to counsel patients on their 
overall reproductive potential.   
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